ArticleAddictive behaviors2020
Cue salience of the use of an electronic nicotine delivery system (ENDS) device marketed to women.
Article in Addictive behaviors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Reactivity to electronic nicotine delivery system (ENDS) cues in adults who smoke cigarettes and vape cannabis.Addictive behaviors · 2026Article
- Examining Electronic Nicotine Delivery System (ENDS) Cue Reactivity Using a Remote Platform: Cigarette and ENDS Desire in Dual Users.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Article
- Electronic cigarette cue reactivity in exclusive electronic cigarette users.Drug and alcohol dependence · 2025Article
- Cue Reactivity to Electronic Cigarettes: A Systematic Review.Substance abuse : research and treatment · 2022Review
- Electronic nicotine delivery systems (ENDS) cue reactivity in dual users: A combined analysis.Drug and alcohol dependence · 2021Article
- Effects of Visual Exposure to IQOS Use on Smoking Urge and Behavior.Tobacco regulatory science · 2021Article
- Vaping in the Workplace: Implications for Employer-Sponsored Tobacco Cessation Programs.Journal of occupational and environmental medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionPassive exposure to the use of electronic nicotine delivery systems (ENDS or e-cigarettes) has been shown to generalize as a smoking cue. As young adult women in particular are increasingly targeted by ENDS distributors, the present study examined whether passive exposure to the use of a female-marketed ENDS product selectively enhanced smoking urge, cigarette and e-cigarette desire, and smoking behavior among women (vs men) smokers.
methodsUsing a mixed design, young adult smokers (n = 64; mean age 28.2 yrs.; ≥5 cigarettes/day) observed a study confederate drink bottled water (control cue) and then vape a female-marketed tank-based ENDS (active cue). Main measures were the Brief Questionnaire of Smoking Urges (BQSU) and visual analog scales (VAS) for cigarette and e-cigarette desire pre- and post-cue exposure, followed by a smoking latency task.
resultsCompared to the control cue, the female-marketed ENDS cue increased smoking urge and desire for cigarettes and e-cigarettes to a similar extent in women and men. It also affected subsequent smoking behavior similarly between the sexes, with 68% of men and 58% of women opting to smoke (vs. obtaining monetary reinforcers).
conclusionsBoth women and men were sensitive to the use of the female-marketed ENDS as a smoking cue. Consistent with prior work by our group, findings demonstrate the cue salience of ENDS, which may be attributable to the aspects of vaping that resemble traditional smoking (e.g. hand-to-mouth and inhalation and exhalation behaviors).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.